INDINOL FORTO AND EGALLOHIT IN THE TREATMENT OF CONDYLOMA ACUMINATE AND GIANT CONDYLOMA

Cover Page


Cite item

Full Text

Abstract

Genital papilloma virus is one of the commonest sexually transmitted disease. Its treatment is still under development and relapses are frequent. The article presents the results of the study of indolecarbinol (Indinol Forto) for the prevention of recurrent genital warts in 75  patients with genital or anal condyloma acuminata, BuschkeLowenstein tumor and bowenoid papulosis, after photodynamic therapy (PDT), cryodestruction, electrocoagulation or Mardil Selen application. Seven patients with Buschke-Lowenstein tumor underwent PDT with subsequent application of Egallohit gel on the lesions. Indolecarbinol 400 mg daily was prescribed for 3 months in combination with alpha2b-interferon (Viferon) 1 million IU daily during 1–3 months. No recurrences were observed during follow-up (mean follow-up duration was 3.9±2.7 years, from 5  months to 9  years). In patients with BuschkeLowenstein tumor, PDT with subsequent Egallohit application resulted in the formation of thin and cosmetically acceptable zones of atrophic scars. The article includes three case reports of patients with Buschke-Lowenstein tumor.

About the authors

V. A. Molochkov

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Author for correspondence.
Email: derma@monikiweb.ru
MD, PhD, Professor, Head of the Dermatovenereology and Dermato-Oncology Department Россия

Yu. V. Molochkova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: fake@neicon.ru
Research Associate, Dermatovenereology and Dermato-Oncology Department Россия

References

  1. Kribauer R, Lenz P, Okun MM. Human papillomavirus. In: Bolognia JL, editor. Dermatology. Edinburg: Mosby; 2002. p. 1217–34.
  2. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RB, Kirnbauer R. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol. 2013;133(12):2706–13.
  3. Рахматулина МР. Новые возможности комплексной терапии аногенитальной папилло-мавирусной инфекции. Вестник дерматологии и венерологии. 2011;23(2):79–84. (Rakhmatulina MR. [New potential of the complex therapy of anogenital papilloma viral infection]. Vestnik dermatologii i venerologii. 2011;(2):79–84. Russian).
  4. Baken LA, Koutsky LA, Kuypers J, Kosorok MR, Lee SK, Kiviat NB, Holmes KK. Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J Infect Dis. 1995;171(2):429–32.
  5. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis. 2006;6(1):21–31.
  6. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2): 278–85.
  7. Zur Hausen H. Papillomavirus infections – a major cause of human cancers. Biochim Biophys Acta. 1996;1288(2):F55–78.
  8. Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013; 445(1–2):21–34.
  9. De Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013; 445(1–2):2–10.
  10. Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect. 1999;75(5):312–6.
  11. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, Wheeler CM. Determinants of genital human papillomavirus detection in a US population. J Infect Dis. 2001;183(11): 1554–64.
  12. Киселев ВИ. Вирусы папилломы человека в развитии рака шейки матки. М.: Дмитрейд График Групп; 2004. 180 с. (Kiselev VI. Human papilloma virus in the development of cervical cancer. Moscow: Dmitreyd Grafik Grupp; 2004. 180 p. Russian).
  13. Henquet CJ. Anogenital malignancies and pre-malignancies. J Eur Acad Dermatol Venereol. 2011;25(8):885–95.
  14. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991;265(4):472–7.
  15. Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. N Engl J Med. 1985;313(13): 784–8.
  16. Horn TD, Johnson SM, Helm RM, Roberson PK. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol. 2005;141(5):589–94.
  17. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645–51.
  18. Jin L, Qi M, Chen DZ, Anderson A, Yang GY, Arbeit JM, Auborn KJ. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res. 1999;59(16):3991–7.
  19. Маликова ЛВ, Нечунаева ТГ, Задонцева НС, Лазарев АФ. В: Лазарев АФ, ред. Профилактика и лечение злокачественных новообразований в современных условиях. Материалы Всероссийской научно-практической конференции. Барнаул; 2007. c. 152. (Malikova LV, Nechunaeva TG, Zadontseva NS, Lazarev AF. In: Lazarev AF, editor. Prevention and treatment of malignancies in the current context. All-Russia Research-to-Practice Conference proceedings. Barnaul; 2007. р. 152. Russian).
  20. Молочков ВА, Семенова ТБ, Киселев ВИ, Молочков АВ. Генитальные вирусные инфекции. Руководство для венерологов. М.: БИНОМ; 2009.
  21. (Molochkov VA, Semenova TB, Kiselev VI, Mo-lochkov AV. Genital viral infections. Guidance for Venereologists. Moscow: BINOM; 2009. Russian).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Molochkov V.A., Molochkova Y.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies